Inactive Instrument

Aerie Pharmaceuticals, Inc.

AERI

US00771V1089

Aerie Pharmaceuticals, Inc. Announces Revenue Guidance for the Full Year for 2022

February 24, 2022 at 04:17 pm EST

Aerie Pharmaceuticals, Inc. provided the full year guidance for 2022, Glaucoma franchise net product revenues: target is $130 million to $140 million, up 16% to 25% versus 2021.

Latest news about Aerie Pharmaceuticals, Inc.

Alcon Completes Acquisition of Aerie Pharmaceuticals for $930 Million	22-11-22	MT
Alcon Concludes $930 Million Purchase of US-based Aerie Pharmaceuticals	22-11-22	MT
Aerie Pharmaceuticals, Inc. Announces Executive Changes	22-11-21	CI
Aerie Pharmaceuticals, Inc. Announces Executive Changes	22-11-21	CI
Aerie Pharmaceuticals, Inc. Announces Management Changes	22-11-21	CI
Aerie Pharmaceuticals, Inc.(NasdaqGM:AERI) dropped from NASDAQ Composite Index	22-11-21	CI
Aerie Pharmaceuticals, Inc.(NasdaqGM:AERI) dropped from S&P TMI Index	22-11-21	CI
Aerie Pharmaceuticals, Inc.(NasdaqGM:AERI) dropped from S&P Global BMI Index	22-11-21	CI
Alcon Research, Ltd. completed the acquisition of Aerie Pharmaceuticals, Inc. from a group of shareholders.	22-11-20	CI
Aerie Pharmaceuticals, Inc.(NasdaqGM:AERI) dropped from NASDAQ Biotechnology Index	22-11-18	CI
Aerie Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Earnings Flash (AERI) AERIE PHARMACEUTICALS Reports Q3 Loss $-0.27	22-11-03	MT
Earnings Flash (AERI) AERIE PHARMACEUTICALS Posts Q3 Revenue $36.1M	22-11-03	MT
Transcript : Aerie Pharmaceuticals, Inc. - Special Call	22-09-23
North American Morning Briefing : Dow Futures Jump -2-	22-08-30	DJ
Citigroup Downgrades Aerie Pharmaceuticals to Neutral From Buy	22-08-29	MT
North American Morning Briefing : Stocks to Gain -2-	22-08-25	DJ
HC Wainwright Downgrades Aerie Pharmaceuticals to Neutral From Buy	22-08-24	MT
Sector Update: Health Care Stocks Declining in Late Trade	22-08-23	MT
Alcon to Acquire Aerie Pharmaceuticals in $770 Million Deal	22-08-23	MT
Sector Update: Health Care Stocks Dropping in Afternoon Trade	22-08-23	MT
Alcon to Acquire Aerie Pharmaceuticals in $770 Million Deal; Shares Rise Tuesday	22-08-23	MT
Truist Securities Downgrades Aerie Pharmaceuticals to Hold From Buy, Raises Price Target to $15.25 From $13	22-08-23	MT
Wall Street Stabilizes Pre-Bell After Slump Fueled by Rate Hike Concerns	22-08-23	MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday	22-08-23	MT

Chart Aerie Pharmaceuticals, Inc.

Duration

Period

More charts

Aerie Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions, including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). The Company's commercial products include Rhopressa and Rocklatan. Rhopressa is a once-daily eye drop designed to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa increases the outflow of aqueous humor through the trabecular meshwork (TM), which accounts for approximately 80% of fluid drainage from the healthy eye and is the diseased tissue responsible for elevated IOP in glaucoma. Rocklatan is a once-daily fixed-dose combination of Rhopressa and latanoprost, a drug for the treatment of patients with open-angle glaucoma or ocular hypertension.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+32.36%	709B
NOVO NORDISK A/S	+30.77%	595B
JOHNSON & JOHNSON	-1.60%	367B
MERCK & CO., INC.	+20.07%	334B
ABBVIE INC.	+6.04%	289B
ASTRAZENECA PLC	+14.77%	239B
NOVARTIS AG	+9.13%	211B
ROCHE HOLDING AG	-3.97%	203B
AMGEN INC.	+9.27%	171B

Other Pharmaceuticals